×ðÁú¿­Ê±

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
News information
ÐÂÎÅ×ÊѶ

GLP-1 ÊÜÌ弤¶¯¼ÁµÄÉú³¤

2023-10-19
|
»á¼ûÁ¿£º

×ðÁú¿­Ê±Çë»Ø¸²ÎªÄú½â˵GLP-1 ÊÜÌ弤¶¯¼ÁµÄÉú³¤¡£

ÒȸßѪÌÇËØÑùëÄ-1£¨GLP-1£©ÊÜÌ弤¶¯¼Á½á¹¹×î¶àµÄ˳Ӧ֢Ϊ2ÐÍÌÇÄò²¡ºÍ·ÊÅÖÖ¢¡£

GLP-1 receptor agonists are now used for the treatment of type 2 diabetes and obesity.

»ØÊ×ÒÔǰ£¬´Ó·¢Ã÷GLP-1ÊÇÒȸßѪÌÇËØÔ­¾­Ã¸´ÙÁѽâºó±¬·¢µÄ£¬ÔÙµ½Exendent-4 µÄ·¢Ã÷¡£

Looking back, GLP-1 was found to be a cleavage product of proglucagon processing.

Exendent-4 ÊÇGLP-1Éú³¤Ê·ÉϵÄÒ»¸öÒªº¦µÄÍ»ÆÆ¡£Exendent-4ÊÇÒ»ÖÖ¶ÔGLP-1ÊÜÌå¾ßÓм¤Ðж¯Óõ«ÄܶԿ¹DPP-4½µ½âµÄëÄ¡£Ë¾ÃÀ¸ñ³ëÄÊÇÈ«ÇòÊ׿î¿Ú·þµÄGLP-1ÊÜÌ弤¶¯¼Á¡£

A key breakthrough came from the discovery of exendent-4. Exendent-4 is a peptide with agonistic properties at the GLP-1 receptor but resistance to degradation by DPP-4.Semiglutide, the first oral GLP-1 receptor agonist marked the next milestone.

Ïà¹ØÍÆ¼ö£º

×ðÁú¿­Ê±¡°GLP-1¡±ÐÂÒ©Ñз¢Ð§ÀÍÆ½Ì¨

×ðÁú¿­Ê±ÄÚÉøÍ¸¼°´úлÐÔ¼²²¡Ä£×Ó

Ïà¹ØÐÂÎÅ
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿